nelfinavir has been researched along with Scleroderma, Systemic in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Fuselier, T; Gongora, R; Lasky, JA; MacKinnon, SS; Molinski, SV; Mondal, D; Sanchez, CG; Sosulski, M | 1 |
| McHugh, J | 1 |
2 other study(ies) available for nelfinavir and Scleroderma, Systemic
| Article | Year |
|---|---|
The Antiretroviral Agent Nelfinavir Mesylate: A Potential Therapy for Systemic Sclerosis.
Topics: Animals; Anti-Retroviral Agents; Cell Culture Techniques; Cell Differentiation; Computer Simulation; Disease Models, Animal; Fibroblasts; Humans; Lung; Male; Mice; Mice, Inbred C57BL; Nelfinavir; Pulmonary Fibrosis; Scleroderma, Systemic; Signal Transduction; Skin; Transforming Growth Factor beta1 | 2018 |
Systemic sclerosis: Antiviral drug inhibits lung fibrosis.
Topics: Anti-Retroviral Agents; Antiviral Agents; Humans; Nelfinavir; Pulmonary Fibrosis; Scleroderma, Systemic | 2017 |